These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29071508)

  • 41. Endocrinopathies in the family of endoplasmic reticulum (ER) storage diseases: disorders of protein trafficking and the role of ER molecular chaperones.
    Kim PS; Arvan P
    Endocr Rev; 1998 Apr; 19(2):173-202. PubMed ID: 9570036
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity.
    Fan JQ
    Biol Chem; 2008 Jan; 389(1):1-11. PubMed ID: 18095864
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi.
    Farinha CM; Matos P; Amaral MD
    FEBS J; 2013 Sep; 280(18):4396-406. PubMed ID: 23773658
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chaperone therapy for molecular pathology in lysosomal diseases.
    Suzuki Y
    Brain Dev; 2021 Jan; 43(1):45-54. PubMed ID: 32736903
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nanochaperone-Based Strategies to Control Protein Aggregation Linked to Conformational Diseases.
    Caballero AB; Gamez P
    Angew Chem Int Ed Engl; 2021 Jan; 60(1):41-52. PubMed ID: 32706460
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Small-molecule modulation of cellular chaperones to treat protein misfolding disorders.
    Sloan LA; Fillmore MC; Churcher I
    Curr Opin Drug Discov Devel; 2009 Sep; 12(5):666-81. PubMed ID: 19736625
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vivo aspects of protein folding and quality control.
    Balchin D; Hayer-Hartl M; Hartl FU
    Science; 2016 Jul; 353(6294):aac4354. PubMed ID: 27365453
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacoperones: targeting therapeutics toward diseases caused by protein misfolding.
    Ulloa-Aguirre A; Zariñán T; Conn PM
    Rev Invest Clin; 2015; 67(1):15-9. PubMed ID: 25857579
    [TBL] [Abstract][Full Text] [Related]  

  • 49. On the design of broad based screening assays to identify potential pharmacological chaperones of protein misfolding diseases.
    Naik S; Zhang N; Gao P; Fisher MT
    Curr Top Med Chem; 2012; 12(22):2504-22. PubMed ID: 23339304
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A cure for traffic jams: small molecule chaperones in the endoplasmic reticulum.
    Römisch K
    Traffic; 2004 Nov; 5(11):815-20. PubMed ID: 15479447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhanced binding to the molecular chaperone BiP slows thyroglobulin export from the endoplasmic reticulum.
    Muresan Z; Arvan P
    Mol Endocrinol; 1998 Mar; 12(3):458-67. PubMed ID: 9514162
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Development of Biological Response Modifiers Based on Unique Medicinal Chemical Strategy].
    Hashimoto Y
    Yakugaku Zasshi; 2021; 141(1):1-13. PubMed ID: 33390437
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug development and the cellular quality control system.
    Conn PM; Janovick JA
    Trends Pharmacol Sci; 2009 May; 30(5):228-33. PubMed ID: 19307028
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Endoplasmic Reticulum-Targeted Subunit Toxins Provide a New Approach to Rescue Misfolded Mutant Proteins and Revert Cell Models of Genetic Diseases.
    Adnan H; Zhang Z; Park HJ; Tailor C; Che C; Kamani M; Spitalny G; Binnington B; Lingwood C
    PLoS One; 2016; 11(12):e0166948. PubMed ID: 27935997
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chemical chaperones: mechanisms of action and potential use.
    Papp E; Csermely P
    Handb Exp Pharmacol; 2006; (172):405-16. PubMed ID: 16610368
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An adaptable standard for protein export from the endoplasmic reticulum.
    Wiseman RL; Powers ET; Buxbaum JN; Kelly JW; Balch WE
    Cell; 2007 Nov; 131(4):809-21. PubMed ID: 18022373
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmaceutical Chaperones and Proteostasis Regulators in the Therapy of Lysosomal Storage Disorders: Current Perspective and Future Promises.
    Mohamed FE; Al-Gazali L; Al-Jasmi F; Ali BR
    Front Pharmacol; 2017; 8():448. PubMed ID: 28736525
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pharmacological chaperones: a potential therapeutic treatment for conformational diseases].
    Mendre C; Mouillac B
    Med Sci (Paris); 2010; 26(6-7):627-35. PubMed ID: 20619166
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacological chaperones for enzyme enhancement therapy in genetic diseases.
    Aymami J; Barril X; Rodríguez-Pascau L; Martinell M
    Pharm Pat Anal; 2013 Jan; 2(1):109-24. PubMed ID: 24236974
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Introduction: molecular chaperones of the ER: their role in protein folding and genetic disease.
    Brooks DA
    Semin Cell Dev Biol; 1999 Oct; 10(5):441-2. PubMed ID: 10597626
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.